The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
IL-6 secreted by cancer-associated fibroblasts promotes epithelial-mesenchymal transition and metastasis of gastric cancer via JAK2/STAT3 signaling pathway
Open accessAbstract
// Xiongyan Wu 1, * , Pan Tao 1, * , Quan Zhou 1, * , Jie Li 1 , Zhenjia Yu 1 , Xiaofeng Wang 1 , Jiaanfang Li 1 , Chen Li 1 , Min Yan 1 , Zhenggang Zhu 1 , Bingya Liu 1 , Liping Su 1 1 Department of Surgery, Shanghai Key Laboratory of Gastric Neoplasms, Shanghai Institute of Digestive Surgery, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200025, People’s Republic of China * These authors contributed equally to this work Correspondence to: Liping Su, email: suliping@shsmu.edu.cn Keywords: cancer-associated fibroblasts, interleukin-6, JAK/STAT3, gastric cancer Received: July 22, 2016 Accepted: January 23, 2017 Published: February 06, 2017 ABSTRACT Cancer-associated fibroblasts (CAFs), as the activated fibroblasts in tumor stroma, are important modifiers of tumor progression. However, the molecular mechanisms underlying the tumor-promoting properties of CAFs in gastric cancer remain unclear. Here, we show that CAFs isolated from gastric cancer produce significant amounts of interleukin-6 (IL-6). CAFs enhances the migration and EMT of gastric cancer cells through the secretion of IL-6 that activates Janus kinase 2/signal transducers and activators of transcription (JAK2/STAT3) pathway in gastric cancer cells, while deprivation of IL-6 using a neutralizing antibody or inhibition of JAK/STAT3 pathway with specific inhibitor AG490 markedly attenuates these phenotypes in gastric cancer cells induced by CAFs. Moreover, silencing IL-6 expression in CAFs or inhibiting JAK2/STAT3 pathway in gastric cancer cells impairs tumor peritoneal metastasis induced by CAFs in vivo . Taken together, these results suggest that CAFs in the tumor microenvironment promote the progression of gastric cancer through IL-6/JAK2/STAT3 signaling, and IL-6 targeted therapy could be a complementary approach against gastric cancer by exerting their action on stromal fibroblasts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global cancer statistics, 2012
Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet‐Tieulent, J., & Jemal, A. (2015) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21262 · Cited by 26,850
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
Epithelial–mesenchymal transitions in tumour progression
Thiery, J. P. (2002) · Nature Reviews Cancer · doi:10.1038/nrc822 · Cited by 6,628
Kalluri, R., & Zeisberg, M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1877 · Cited by 4,538
Massagué, J. (2008) · Cell · doi:10.1016/j.cell.2008.07.001 · Cited by 3,907
Orimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759
Epithelial-Mesenchymal Transition: At the Crossroads of Development and Tumor Metastasis
Yang, J., & Weinberg, R. A. (2008) · Developmental Cell · doi:10.1016/j.devcel.2008.05.009 · Cited by 3,012
Stromal fibroblasts in cancer initiation and progression
Bhowmick, N. A., Neilson, E. G., & Moses, H. L. (2004) · Nature · doi:10.1038/nature03096 · Cited by 2,302
Biomarkers for epithelial-mesenchymal transitions
Zeisberg, M., & Neilson, E. G. (2009) · Journal of Clinical Investigation · doi:10.1172/jci36183 · Cited by 2,299
Zheng, X., Carstens, J. L., Kim, J., Scheible, M., Kaye, J., Sugimoto, H., Wu, C.-C., LeBleu, V. S., & Kalluri, R. (2015) · Nature · doi:10.1038/nature16064 · Cited by 2,032
Erez, N., Truitt, M., Olson, P., & Hanahan, D. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.041 · Cited by 1,515
Cancer-Associated Fibroblasts: Their Characteristics and Their Roles in Tumor Growth
Shiga, K., Hara, M., Nagasaki, T., Sato, T., Takahashi, H., & Takeyama, H. (2015) · Cancers · doi:10.3390/cancers7040902 · Cited by 774
Cancer associated fibroblasts: the dark side of the coin.
Cirri, P., & Chiarugi, P. (2011) · Europe PMC (PubMed Central) · Cited by 654
Constitutive activation of STAT 3 in breast cancer cells: A review
Banerjee, K., & Resat, H. (2016) · International Journal of Cancer · doi:10.1002/ijc.29923 · Cited by 611
Inflammation and Cancer: IL-6 and STAT3 Complete the Link
Bromberg, J., & Wang, T. C. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.009 · Cited by 542
Yadav, A., Kumar, B., Datta, J., Teknos, T. N., & Kumar, P. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-11-0271 · Cited by 503
Interleukin-6 - A Key Regulator of Colorectal Cancer Development
Waldner, M. J., Foersch, S., & Neurath, M. F. (2012) · International Journal of Biological Sciences · doi:10.7150/ijbs.4614 · Cited by 418
Nagasaki, T., Hara, M., Nakanishi, H., Takahashi, H., Sato, M., & Takeyama, H. (2014) · British Journal of Cancer · doi:10.1038/bjc.2013.748 · Cited by 385
The IL-6/JAK/STAT3 pathway: Potential therapeutic strategies in treating colorectal cancer
WANG, S.-W., & SUN, Y.-M. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2259 · Cited by 320
LIU, R.-Y., ZENG, Y., LEI, Z., WANG, L., YANG, H., LIU, Z., ZHAO, J., & ZHANG, H.-T. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2310 · Cited by 308
Yang, F., Tuxhorn, J. A., Ressler, S. J., McAlhany, S. J., Dang, T. D., & Rowley, D. R. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1702 · Cited by 278
Augsten, M., Hägglöf, C., Olsson, E., Stolz, C., Tsagozis, P., Levchenko, T., Frederick, M. J., Borg, Å., Micke, P., Egevad, L., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813144106 · Cited by 242
Li, P., Shan, J.-X., Chen, X.-H., Zhang, D., Su, L.-P., Huang, X.-Y., Yu, B.-Q., Zhi, Q.-M., Li, C.-L., Wang, Y.-Q., et al. (2015) · Cell Research · doi:10.1038/cr.2015.51 · Cited by 173
Self-citationInterleukin-6: A multifunctional targetable cytokine in human prostate cancer
Culig, Z., & Puhr, M. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.05.033 · Cited by 170
Hu, T., Yao, Y., Yu, S., Han, L., Wang, W., Guo, H., Tian, T., Ruan, Z.-P., Kang, X., Wang, J., et al. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.08.012 · Cited by 149
Augmented gp130‐mediated cytokine signalling accompanies human gastric cancer progression
Cb, J., Judd, L. M., Menheniott, T. R., Kronborg, I., Dow, C., Yeomans, N. D., Boussioutas, A., Robb, L. G., & Giraud, A. (2007) · The Journal of Pathology · doi:10.1002/path.2218 · Cited by 122
Du, R., Xia, L., Ning, X., Liu, L., Sun, W., Huang, C., Wang, H., & Sun, S. (2014) · Molecular Biology of the Cell · doi:10.1091/mbc.e14-01-0044 · Cited by 118
Kim, M. S., Lee, W. S., Jeong, J., Kim, S., & Jin, W. (2015) · Oncotarget · doi:10.18632/oncotarget.5522 · Cited by 108
Wu, X., Chen, X., Zhou, Q., Li, P., Yu, B., Li, J., Qu, Y., Yan, J., Yu, Y., Yan, M., et al. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.02.002 · Cited by 98
Self-citationInterleukin-6 Mediates Epithelial–Stromal Interactions and Promotes Gastric Tumorigenesis
Kinoshita, H., Hirata, Y., Nakagawa, H., Sakamoto, K., Hayakawa, Y., Takahashi, R., Nakata, W., Sakitani, K., Serizawa, T., Hikiba, Y., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060914 · Cited by 97
Elliott, B. E., Hung, W., Boag, A. H., & Tuck, A. B. (2002) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y02-010 · Cited by 93
Benwell, R. K., & Lee, D. R. (2009) · Clinical Immunology · doi:10.1016/j.clim.2009.09.013 · Cited by 61
Cancer-associated fibroblasts as target and tool in cancer therapeutics and diagnostics
Vlieghere, E. D., Verset, L., Demetter, P., Bracke, M., & Wever, O. D. (2015) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-015-1818-4 · Cited by 51
Galdiero, M., Vitiello, M., D’Isanto, M., Raieta, K., & Galdiero, E. (2006) · Cytokine · doi:10.1016/j.cyto.2006.12.003 · Cited by 46
Targeting IL-6 for the treatment of rheumatoid arthritis: Phase II investigational drugs
Semerano, L., Thiolat, A., Minichiello, É., Clavel, G., Bessis, N., & Boissier, M. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.912276 · Cited by 42
Bae, Y. K., Choi, J. E., Kang, S. H., & Lee, S. J. (2015) · Journal of Breast Cancer · doi:10.4048/jbc.2015.18.3.256 · Cited by 40
Cited by
Role of Matrix Metalloproteinases in Angiogenesis and Cancer
Quintero-Fabián, S., Arreola, R., Becerril-Villanueva, E., Torres-Romero, J. C., Arana-Argáez, V., Lara-Riegos, J., Ramírez-Camacho, M. A., & Alvarez-Sánchez, M. E. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01370 · Cited by 1,036
Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer
Wu, F., Yang, J., Liu, J., Wang, Y., Mu, J., Zeng, Q., Deng, S., & Zhou, H. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00641-0 · Cited by 773
Gastric cancer: a comprehensive review of current and future treatment strategies
Sexton, R. E., Al Hallak, M. N., Diab, M., & Azmi, A. S. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09925-3 · Cited by 772
Fiori, M. E., Di Franco, S., Villanova, L., Bianca, P., Stassi, G., & De Maria, R. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0994-2 · Cited by 647
The role of IL-6/JAK2/STAT3 signaling pathway in cancers
Huang, B., Lang, X., & Li, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1023177 · Cited by 479
Metadata
- Authors
- Wu, X., Tao, P., Zhou, Q., Li, J., Yu, Z., Wang, X., Li, J., Li, C., Yan, M., Zhu, Z., Liu, B., & Su, L.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2017-02-06
- Volume
- 8
- Issue
- 13
- Pages
- 20741-20750
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2587319667
- Cited by
- 367
- References
- 36
- FWCI
- 12.93
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.